TP53基因在弥漫性大B细胞淋巴瘤中作用的研究进展  

Research Progress of Role of TP53 Gene in Diffuse Large B-cell Lymphoma

作　　者：余昌敏 王华 YU Changmin;WANG Hua(The Second School of Clinical Medicine of Binzhou Medical University,Yantai 264100,China;Department of Hematology,Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264100,China)

机构地区：[1]滨州医学院第二临床医学院,山东烟台264100 [2]滨州医学院烟台附属医院血液内科,山东烟台264100

出　　处：《医学综述》2024年第21期2643-2647,共5页Medical Recapitulate

摘　　要：弥漫性大B细胞淋巴瘤(DLBCL)是全世界范围内发病率和病死率较高的恶性肿瘤之一。目前以药物治疗为主的综合治疗可有效改善DLBCL患者的转归,但仍有部分患者疗效不佳。抑癌基因TP53在肿瘤发生、发展过程中发挥着至关重要的作用,其表达变化与肿瘤细胞增殖、侵袭及迁移密切相关。TP53基因突变对DLBCL的发生、发展及预后分层的影响是近年研究的热点。深入研究TP53基因突变对DLBCL预后的影响,可为其靶向治疗及预后判断提供信息参考,且具有重要的临床应用价值。Diffuse large B-cell lymphoma(DLBCL)is one of the malignant tumors with high morbidity and mortality worldwide.Comprehensive treatment based on drug therapy can effectively improve the prognosis of patients with DLBCL,but there are still some patients with poor efficacy.In the process of tumorigenesis and development,oncogene TP53 plays a crucial role,and its expression changes are closely related to tumor cell proliferation,invasion and migration.The impact of its mutation on the occurrence,development and prognostic stratification of DLBCL is a hot research spot in recent years.In-depth exploration of the effect of TP53 gene mutations on the prognosis of DLBCL can provide information and reference for the targeted therapy and prognosis judgement,which has great clinical application value.

关 键 词：弥漫性大B细胞淋巴瘤 TP53基因 基因突变 预后分层 靶向治疗 

分 类 号：R733[医药卫生—肿瘤]